GSK Drug Pipeline

GSK maintains a substantial clinical portfolio, with 132 active trials out of 2003 total trials registered since 2008. These active programs span from Phase 1 through Phase 4, with 46, 55, 43, and 7 trials respectively. The portfolio covers 15 therapeutic areas, but is heavily concentrated in Oncology, which accounts for 48% of active programs with 63 trials. Within Oncology, the leading indications are Solid Tumor (Advanced) with 29 active trials including 7 in Phase 3, Multiple Myeloma with 18 active trials including 7 in Phase 3, and Lung Cancer (General) with 5 active trials including 3 in Phase 3. Beyond Oncology, the next most active therapeutic areas are Infectious Disease (20 active trials), Respiratory (16 active trials), Metabolic (5 active trials), Immunology (4 active trials), and CNS (2 active trials). The significant number of Phase 3 trials in Solid Tumor and Multiple Myeloma suggest a potential for near-term catalysts within the Oncology portfolio.